Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease
Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease
复制标题
雌激素替代疗法对阿尔茨海默病患者他克林反应的影响
作者：
L. Schneider;M. Farlow;V. Henderson;J. Pogoda
目的：探讨雌激素替代疗法(ERT)是否影响阿尔茨海默病(AD)患者对他克林的临床和认知反应。设计：一项为期30周的随机、双盲、安慰剂对照、平行分组、多中心的他克林临床试验，其中一部分妇女在随机化前接受ERT。患者：参与先前报道的试验的妇女，患有轻度至中度AD，年龄至少50岁。干预：随机分配给安慰剂或他克林三种递增剂量方案中的一种：最大剂量为80 mg/d、120 mg/d或160 mg/d。观察指标：阿尔茨海默病评定量表-认知量表(ADASc)、临床医生访谈改变印象(Cibi)、简易精神状态检查(MMSE)、照顾者改变印象(CIC)。结果：在318名有可评估数据的妇女中，14.5%接受了ERT。完成试验的服用ERT和他克林的妇女比没有接受ERT的妇女改善得更多，这些妇女被随机分配到ADASC(p<；0.01)、Cibi(p=0.02)、CIC(p=0.006)和MMSE(p=0.07)中进行评估。使用意向治疗分析，他们在ADASC上有显著改善(p=0.01)。结论：先前和持续的ERT可增强AD女性患者对他克林的反应。需要进行随机试验。神经病学1996；46：1580-1584
Objective: To examine whether estrogen replacement therapy (ERT) affects clinical and cognitive responses to tacrine in women with Alzheimer's disease (AD). Design: A 30-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter clinical trial of tacrine in which a subgroup of women were receiving ERT prior to randomization. Patients: Women with mild to moderate-stage AD, at least 50 years of age, who were enrolled in the previously reported trial. Interventions: Randomized assignment to placebo or to one of three ascending-dosage regimens of tacrine: maximum dosages of 80 mg/d, 120 mg/d, or 160 mg/d. Outcome measures: Alzheimer's Disease Assessment Scale--Cognitive Scale (ADASc), Clinician Interview-Based Impression of change (CIBI), Mini-Mental State Examination (MMSE), Caregiver's Impression of Change (CIC). Results: Of 318 women with evaluable data 14.5% were receiving ERT. Women completing the trial taking ERT and tacrine improved more than women not receiving ERT who were randomly assigned to tacrine or to placebo as assessed by the ADASc (p < 0.01), the CIBI (p = 0.02), the CIC (p = 0.006), and the MMSE (p = 0.07). They improved significantly on the ADASc (p = 0.01) using an intent-to-treat analysis. Conclusions: Prior and continuing ERT may enhance response to tacrine in women with AD. Randomized trials are needed. NEUROLOGY 1996;46: 1580-1584
DOI：
10.1176/ajp.141.11.1356
发表时间：
1984-11
期刊：
The American journal of psychiatry
影响因子：
--
作者：
W. Rosen;R. Mohs;K. Davis
通讯作者：
W. Rosen;R. Mohs;K. Davis
将半抗原二硝基苯酚 (DNP) 重新呈递给 DNP 特异性 T 细胞系。
影响因子：
4.3
作者：
Chang,JC;Ishioka,GI;Moorhead,JW
通讯作者：
Moorhead,JW